Sab Biotherapeutics Stock Cash Flow From Operations
| SABS Stock | USD 2.55 0.05 1.92% |
Fundamental analysis of SAB Biotherapeutics allows traders to better anticipate movements in SAB Biotherapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. SAB Biotherapeutics Company Cash Flow From Operations Analysis
SAB Biotherapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current SAB Biotherapeutics Cash Flow From Operations | (34.29 M) |
Most of SAB Biotherapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, SAB Biotherapeutics has (34.29 Million) in Cash Flow From Operations. This is 106.5% lower than that of the Biotechnology sector and 154.85% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.53% higher than that of the company.
SAB Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in cash flow from operations category among its peers.
SAB Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (111.93) % | ||||
| Current Valuation | 17.62 M | ||||
| Shares Outstanding | 9.29 M | ||||
| Shares Owned By Insiders | 21.00 % | ||||
| Shares Owned By Institutions | 20.93 % | ||||
| Number Of Shares Shorted | 21.05 K | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 62.69 X | ||||
| Revenue | 1.32 M | ||||
| Gross Profit | (29.39 M) | ||||
| EBITDA | (28.99 M) | ||||
| Net Income | (34.11 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 4.67 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 2.30 X | ||||
| Cash Flow From Operations | (34.29 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (3.70) X | ||||
| Target Price | 11.6 | ||||
| Number Of Employees | 63 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 23.69 M | ||||
| Total Asset | 44.2 M | ||||
| Retained Earnings | (124.17 M) | ||||
| Working Capital | 15.81 M | ||||
| Net Asset | 44.2 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.